With positive data from a Phase IIa trial in hand, Actelion AG plans to move directly into a Phase III morbidity/mortality trial of its first-in-class oral prostacyclin (PGI2) receptor agonist in pulmonary arterial hypertension (PAH) before year-end. (BioWorld International) Read More
